Advertisement

Therapie des Diabetes mellitus

  • D. Pittrow

Zusammenfassung

Der Diabetes mellitus gehört zu den Volkskrankheiten: Die großangelegte epidemiologische Studie HYDRA zeigte, dass 18% der Männer und 14% der Frauen, die einen Hausarzt aufsuchen, an der Erkrankung leiden [1]. Der Diabetes mellitus tritt selten isoliert auf, und viele Patienten leiden gleichzeitig an Begleiterkrankungen wie arterieller Hypertonie, Hyperlipidämie und atherosklerotischen Folgeerkrankungen [1].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Wittchen HU, Krause P, Höfler M et al. Arterielle Hypertonie, Diabetes mellitus und assoziierte Erkrankungen in der Allgemeinarztpraxis. Fortschr Med 2003; Supple. I (121): 19–27Google Scholar
  2. 2.
    Hanefeld M, Fischer S, Julius U, et al: The DIS-Group: Risk factors for myocardial infarction and death in newly detected in NIDDM: the Diabetes Intervention Study, I1 year follow-up. Diabetologia 1996; 39: 1577–1583PubMedCrossRefGoogle Scholar
  3. 3.
    UKPDS Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53CrossRefGoogle Scholar
  4. 4.
    Praxisleitlinien der Deutschen Diabetes-Gesellschaft (DDG). Diabetes Stoffwechsel 2002; 11 (Suppl. 2): 3–5. Internet: http://www.leitlinien.de/nvlldiabetes.pdfGoogle Scholar
  5. 5.
    American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002; 25(Suppl. 1):S33–49. Internet: http://care.diabetesjournals.org/content/vol25/suppl_1/Google Scholar
  6. 6.
    Schulze J, Rietzsch H: Insulin therapy. In: A practical guide to the therapy of type II diabetes. Pathophysiology, metabolic syndrome, differential therapy, late complications. Hanefeld M (ed.). de Gruyter; Berlin 1995; 160–168Google Scholar
  7. 7.
    UKPDS Study Group. Relative efficacy of sulfonylurea, insulin and metformin therapy in newly diagnosed non-insulin dependent diabetes with primary diet failure followed for six years. UKPDS Study Group. An Int Med 1998; 128: 165–17Google Scholar
  8. 8.
    Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403CrossRefGoogle Scholar
  9. 9.
    Vigneri R, Goldfine ID. Role of metformin in treatment of diabetes mellitus. Diabetes Care 1987; 10: 118–122PubMedCrossRefGoogle Scholar
  10. 10.
    Hermann LS: Metformin: a review of its pharmacological properties and therapeutic use. Diabetes Metab 1990; 5: 233–245Google Scholar
  11. 11.
    Panthen U: Molekularer and zellulärer Wirkungsmechanismus der Sulfonylharnstoffe. Diabetes and Stoffwechsel 1992; 1: 240–242Google Scholar
  12. 12.
    Hanefeld M, Fischer S, Schulze J et al: Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991; 14: 732–737PubMedCrossRefGoogle Scholar
  13. 13.
    Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 2001; 61; 11: 1625–1660PubMedCrossRefGoogle Scholar
  14. 14.
    Evans AJ, Krentz AJ. Recent developments and emerging therapies for type 2 diabetes mellitus. Drugs R D 1999; 2: 75–94PubMedCrossRefGoogle Scholar
  15. 15.
    Gale EAM. Lessons from the glitazones: a story of drug development Lancet 2001; 357: 1870–75Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • D. Pittrow

There are no affiliations available

Personalised recommendations